Payment overview · 2025
General Payments
$229.30
12 reported records · 8 companies
Healthcare provider profile · identity verified
Stephen Burke, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRISTOL, TN · NPI 1851392492
Verified facts
What the public records show
CMS Open Payments records show Stephen Burke, MD received $229.30 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.98 | 23.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 19.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.46 | 15.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.70 | 12.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.70 | 9.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.56 | 7.7% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.24 | 6.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.66 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.30 | 11 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 660 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 637 | 173 |
| Gabapentin | Gabapentin | 627 | 126 |
| Lisinopril | Lisinopril | 626 | 175 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 626 | 185 |
| Omeprazole | Omeprazole | 613 | 171 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 490 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 473 | 130 |
| Losartan Potassium | Losartan Potassium | 449 | 120 |
| Metformin Hcl Er | Metformin Hcl | 437 | 125 |
| Meloxicam | Meloxicam | 435 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 414 | 112 |
| Hydrochlorothiazide | Hydrochlorothiazide | 393 | 115 |
| Escitalopram Oxalate | Escitalopram Oxalate | 358 | 92 |
| Valsartan | Valsartan | 356 | 96 |
| Alprazolam | Alprazolam | 340 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 95 |
| Montelukast Sodium | Montelukast Sodium | 334 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 76 |
| Tramadol Hcl | Tramadol Hcl | 306 | 55 |
| Eliquis | Apixaban | 295 | 69 |
| Trazodone Hcl | Trazodone Hcl | 287 | 77 |
| Glipizide Er | Glipizide | 283 | 79 |
| Metformin Hcl | Metformin Hcl | 264 | 74 |
| Furosemide | Furosemide | 230 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 217 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 215 | 31 |
| Lorazepam | Lorazepam | 193 | 25 |
| Carvedilol | Carvedilol | 180 | 48 |
| Allopurinol | Allopurinol | 168 | 49 |
| Simvastatin | Simvastatin | 168 | 42 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 158 | 46 |
| Atenolol | Atenolol | 152 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 28 |
| Baclofen | Baclofen | 131 | 32 |
| Potassium Chloride | Potassium Chloride | 131 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 51 |
| Sertraline Hcl | Sertraline Hcl | 125 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 36 |
| Methocarbamol | Methocarbamol | 111 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 32 |
| Spironolactone | Spironolactone | 110 | 30 |
| Buspirone Hcl | Buspirone Hcl | 109 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 23 |
| Celecoxib | Celecoxib | 103 | 31 |
| Clonazepam | Clonazepam | 98 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 23 |
| Warfarin Sodium | Warfarin Sodium | 97 | 27 |
| Ondansetron Odt | Ondansetron | 96 | 38 |
| Estradiol | Estradiol | 93 | 23 |
| Pregabalin | Pregabalin | 92 | 17 |
| Irbesartan | Irbesartan | 90 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 23 |
| Xarelto | Rivaroxaban | 86 | 19 |
| Farxiga | Dapagliflozin Propanediol | 83 | 18 |
| Finasteride | Finasteride | 82 | 23 |
| Naproxen | Naproxen | 79 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 77 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 17 |
| Jardiance | Empagliflozin | 76 | 17 |
| Famotidine | Famotidine | 74 | 26 |
| Nystatin | Nystatin | 74 | 33 |
| Diazepam | Diazepam | 73 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 29 |
| Topiramate | Topiramate | 70 | 14 |
| Ibuprofen | Ibuprofen | 68 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 14 |
| Ezetimibe | Ezetimibe | 65 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Prednisone | Prednisone | 62 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 59 | 15 |
| Bupropion Xl | Bupropion Hcl | 58 | 17 |
| Glimepiride | Glimepiride | 56 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 19 |
| Promethazine Hcl | Promethazine Hcl | 53 | 11 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 14 |
| Donepezil Hcl | Donepezil Hcl | 51 | 12 |
| Fenofibrate | Fenofibrate | 51 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 47 | 12 |
| Ozempic | Semaglutide | 47 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | suppressed |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Fentanyl | Fentanyl | 44 | suppressed |
| Lovastatin | Lovastatin | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Dutasteride | Dutasteride | 42 | 11 |
| Fluconazole | Fluconazole | 42 | 28 |
| Lansoprazole | Lansoprazole | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Primidone | Primidone | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 13 |
| Linzess | Linaclotide | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 39 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Clarithromycin | Clarithromycin | 31 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Nabumetone | Nabumetone | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Benzonatate | Benzonatate | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Azithromycin | Azithromycin | 21 | 19 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Temazepam | Temazepam | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.30 · 12 records | ABBVIE INC. | ETERNA, LEQVIO, Natroba, Ozempic, QULIPTA, Rybelsus, Spinosad, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error